Raymond K. Hau

Drug Transporters at the Human Blood-Testis Barrier

Addressing the Clinical Importance of Equilibrative Nucleoside Transporters in Drug Discovery and Development

In Vitro and In Vivo Models for Drug Transport Across the Blood-Testis Barrier

Localization of Xenobiotic Transporters Expressed at the Human Blood-Testis Barrier

Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients

<scp>PF</scp>‐07321332 (Nirmatrelvir) does not interact with human <scp>ENT1</scp> or <scp>ENT2</scp>: Implications for <scp>COVID</scp>‐19 patients

Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian Modeling

Identification of NMS-873, an allosteric and specific p97 inhibitor, as a broad antiviral against both influenza A and B viruses

In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses

Structure–Property Relationship Studies of Influenza A Virus AM2-S31N Proton Channel Blockers

Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses

Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral